Dr. Overman on Investigational Targeted Therapies in mCRC

(1:46)

Pancreas Cancer: Investigational Targeted Approaches

(6:1econd)

Scholar Rock - New Data on Investigational Muscle-Targeted SMA Treatment

(9:48)

Investigational Approaches for TRK-Fusion Cancers

(10:11)

Taking Hope from Molecularly Targeted Therapy

(4:45)

Challenges in Drug Development for ALS

(55:24)

Investigational Strategies and the Future of TNBC

(3:7)

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

(5:25)

Transitioning Off Steroids and onto New and Investigational Treatments_FSR and aTyr Townhalll

(1:7:14)

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

(20:43)

Jay Bradner - Dana-Farber Targeted Degradation Webinar Series

(52:42)

Investigational Drug Service (IDS) Pharmacy | FSHP Fast Phacts

(3:33)

Dr. Mark Kris on the Combination of Molecularly Targeted Therapies

(1:54)

Investigational approaches targeting BCMA in multiple myeloma

(1:37)

Webinar: Clinical Trial Updates for the Investigational Drug CTX-009

(48:37)

Investigational Device Exemption

(1:27)

Investigational Drug Accountability: Agent Dispensing

(9:35)

Investigational targetted therapeutic, entrectinib, shows promise against range of cancer types

(7:31)

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

(58:27)

Investigational New Drug Safety Reporting Requirements (10of14) REdI 2018

(36:51)